Halozyme Therapeutics Inc (NASDAQ:HALO) Big Money Quarterly Sentiment at 1.25

Halozyme Therapeutics, Inc. (NASDAQ:HALO) Corporate Logo

Halozyme Therapeutics Inc’s Sentiment

“Big money sentiment for Halozyme Therapeutics Inc (NASDAQ:HALO) in Q4 2018 increased to 1.25, SEC filings reveal. So its up 0.22, from 2018Q3’s 1.03. 85 investment managers increased or started new stock positions, while 68 sold and reduced their stakes in Halozyme Therapeutics Inc so the sentiment has improved. These funds own 116.15 million shares, that’s down from 118.32 million shares in 2018Q3. Funds holding Halozyme Therapeutics Inc in top 10 changed to 2 from 3 for a decrease of 1. 25 Investors Sold All; 43 Reduced Holdings; 55 increased stakes while 30 investment managers bought stakes.

Biggest Halozyme Therapeutics Inc Investors

As of Q4 2018 Third Security Llc has 28.12% invested in Halozyme Therapeutics Inc. As of Q4 2018, 8.32 million shares of Halozyme Therapeutics Inc are owned by Bb Biotech Ag. Doheny Asset Management Ca reported 227,193 shares. The California-based fund Snyder Capital Management L P have invested about 2.24% of the investment professional’s stock portfolio in Halozyme Therapeutics Inc. The Minnesota-based fund First Light Asset Management Llc looks positive on Halozyme Therapeutics Inc, owning 938,399 shares.

Halozyme Therapeutics, Inc., a biotechnology company, researches, develops, and commercializes human enzymes and other drug candidates in the United States, Switzerland, and internationally.The company has $2.33 billion market cap. The companyÂ’s human enzymes are used to facilitate the delivery of injected drugs and fluids, enhancing the efficacy and the convenience of other drugs or can be used to alter tissue structures for clinical benefit.Last it reported negative earnings. The Company’s products are based on the Enhanze technology, a patented recombinant human hyaluronidase enzyme that enables the subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.

HALO touched $16.08 during the last trading session after $0.21 change.Halozyme Therapeutics, Inc. is downtrending after having declined 13.07% since March 15, 2018. HALO has 1.83M volume or 139.11% up from normal. HALO underperformed the S&P 500 by 17.44%.

On May, 9. Investors wait Halozyme Therapeutics, Inc. (NASDAQ:HALO) to publish its quarterly earnings, Faxor reports. Analysts forecast $0.01 EPS. That’s $0.20 up or 105.26 % from 2018’s earnings of $-0.19. HALO’s profit could reach $1.45M with 402.00 P/E in case $0.01 EPS is announced. -200.00 % EPS growth is what analysts predict. $-0.01 EPS was announced for last quarter.

22,000 were reported by Sterling Strategies Limited Liability Co. Aperio Gru Llc owns 23,467 shs. Great West Life Assurance Comm Can, a Manitoba – Canada-based fund reported 14,291 shs. Trust Com Of Vermont holds 0% or 200 shs. Us State Bank De holds 0% of its capital in Halozyme Therapeutics, Inc. (NASDAQ:HALO) for 8,208 shs. 27,485 are held by Bnp Paribas Arbitrage. California State Teachers Retirement Systems has 195,436 shs. Axa has 428,217 shs. Hudson Bay Cap Mngmt L P holds 145,000 shs. Elk Creek Limited Liability Company accumulated 740,816 shs. Colony Group Llc stated it has 41,065 shs or 0.03% of all its holdings. Prelude Cap Ltd Llc reported 0% in Halozyme Therapeutics, Inc. (NASDAQ:HALO). 383 are held by Moody Natl Bank Division. 40,632 are owned by Metropolitan Life Insur New York. D E Shaw And Incorporated holds 0.01% of its capital in Halozyme Therapeutics, Inc. (NASDAQ:HALO) for 402,884 shs.

Halozyme Therapeutics, Inc. (NASDAQ:HALO) Ratings Coverage

In total 3 analysts cover Halozyme (NASDAQ:HALO). “Buy” rating has 2, “Sell” are 1, while 0 are “Hold”. 67% are bullish. 6 are the (NASDAQ:HALO)’s analyst reports since November 26, 2018 according to StockzIntelligence Inc. On Tuesday, November 27 the firm has “Buy” rating by JMP Securities given. The company rating was maintained by Barclays Capital on Friday, February 22. On Monday, November 26 the stock of Halozyme Therapeutics, Inc. (NASDAQ:HALO) has “Buy” rating given by Cantor Fitzgerald. The company rating was maintained by Cantor Fitzgerald on Thursday, February 28. On Friday, February 22 Cantor Fitzgerald maintained the shares of HALO in report with “Buy” rating. On Tuesday, February 26 the rating was maintained by JMP Securities with “Buy”.

For more Halozyme Therapeutics, Inc. (NASDAQ:HALO) news published recently go to: Globenewswire.com, Seekingalpha.com, Nasdaq.com, Streetinsider.com or Nasdaq.com. The titles are as follows: “Consolidated Research: 2019 Summary Expectations for Tenaris SA, Rapid7, Halozyme Therapeutics, Cara Therapeutics, EnPro Industries, and K12 — Fundamental Analysis, Key Performance Indications – GlobeNewswire” published on February 15, 2019, “Halozyme Therapeutics, Inc. (HALO) CEO Dr. Helen Torley on Q4 2018 Results – Earnings Call Transcript – Seeking Alpha” on February 21, 2019, “Top Ranked Momentum Stocks to Buy for March 4th – Nasdaq” with a publish date: March 04, 2019, “Halozyme Therapeutics (HALO) Reports FDA Approval of Herceptin Hylecta – StreetInsider.com” and the last “U.S. STOCKS ON THE MOVE-Gap, Walgreen Boots, ImmunoGen, PG&E Corp – Nasdaq” with publication date: March 01, 2019.

Halozyme Therapeutics, Inc. (NASDAQ:HALO) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.